Nonclinical characterization of bexmarilimab, a Clever-1-targeting antibody for supporting immune defense against cancersCharacterization of bexmarilimab

Overview of attention for article published in Molecular Cancer Therapeutics, May 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (71st percentile)
Good Attention Score compared to outputs of the same age and source (70th percentile)

So far, Altmetric has seen 7 X posts from 7 X users, with an upper bound of 5,744 followers.

RT @FaronPharm: Learn more about the early #research supporting our investigational precision #cancer #immunotherapy, #bexmarilimab, in @MC…

RT @FaronPharm: Learn more about the early #research supporting our investigational precision #cancer #immunotherapy, #bexmarilimab, in @MC…

RT @FaronPharm: Learn more about the early #research supporting our investigational precision #cancer #immunotherapy, #bexmarilimab, in @MC…

RT @FaronPharm: Learn more about the early #research supporting our investigational precision #cancer #immunotherapy, #bexmarilimab, in @MC…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 3 additional X posts.